Introduction The aim of this study was to describe the real-word treatment and associated
healthcare resource use (HCRU) of multiple sclerosis (MS) patients, as stratified by different …

Background Primary progressive multiple sclerosis (PPMS) is characterized by development
of more chronic neurological manifestations from disease onset compared with relapsing …

Introduction The healthcare situation of multiple sclerosis (MS) and its course are not being
thoroughly investigated in Japan. We aimed to examine the current healthcare situation …

Background: Multiple sclerosis (MS) is a common cause of neurological disability in young
adults. The TRIBUNE study provides a detailed exploration of costs in relation to relapses …

Multiple sclerosis (MS) experts in Europe are facing rapidly rising demands of excellence
due to the increasing complexity of MS therapy and management. A central European expert …

Background The efficacy and safety of disease-modifying therapies (DMTs) in multiple
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …

Background. Cohort studies and registries provide opportunities to estimate long‐term
outcome in multiple sclerosis. Objectives. To describe changes in disability (EDSS), relapse …

Objective To assist policymakers as they reflect on treatment protocols and approaches for
the efficient delivery of medical care for multiple sclerosis (MS) patients in Japan. Methods …

Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple
sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT …

Background: Multiple sclerosis (MS) is an important, highly disabling neurological disease,
common among young adults in The Netherlands. Nevertheless, only a few studies to date …